2006 Archive

8:30-8:45AM

Welcome and Introduction
Claude Canizares
Associate Provost and Vice President for Research, MIT

8:45-9:00AM

Vaccines: Opportunities and Barriers Across the Value Chain (PDF 1.7MB)
Introduction - Anthony Sinskey , Sc. D.- Session Chair
Professor, Biology and Health Sciences & Technology, MIT
Co-Director Center for Biomedical Innovation

9:00-9:20PM

Session 1: Case Study ROTARIX (PDF 4.3MB)
Una Ryan, Ph.D.
CEO, Avant Immunotherapeutics, Inc.

9:20-10:15AM

Panel Discussion
GK Raju, Ph.D. Moderator
Executive Director of the Pharmaceutical Manufacturing Initiative (PHARMI)
Executive Director, The Consortium for the Advancement of Manufacturing of Pharmaceuticals (CAMP)

Panel Members

• John Mekalanos, Ph.D.
• Department of Microbiology & Molecular Genetics, Harvard Medical School
• Harry Lee Ph.D
• Associate, Research Laboratory of Electronics, MIT
• Howard Golub, M.D., Ph.D.
• President & Co-Founder,BattelleCRO
• Una Ryan, Ph.D.
• CEO, Avant Immunotherapeutics, Inc

10:30-10:50AM

Session 2: Case Study- Malaria: The Ancora Story (PDF 10.7MB)
John Pena, Ph.D.
President, Ancora Pharmaceuticals

10:50-11:45PM

Panel Discussion
Rajeev Ram, Ph.D. Moderator
Associate Professor of Electrical Engineering & Computer Science
Associate Director, Research Laboratory of Electronics, MIT

Panel Members

• John Pena, Ph.D.
• President, Ancora Pharmaceuticals
• Kristala Jones Prather, Ph.D.
• Department of Chemical Engineering, MIT
• William Egan, PhD
• Executive Director, PharmaNet Consulting
• Former Acting Director, Office of Vaccines, FDA
• Howard Golub, M.D., PhD
• President & Co, Founder, BattelleCRO
• Wendy Everett, Sc.D.
• President, New England Healthcare Institute

11:45-12:00PM

Summary and next steps
Anthony Sinskey, Sc. D.
Professor, Biology and Health Sciences & Technology, MIT

1:00-1:20PM

Session 3: CNS Drugs and Pharmaceutical R&D (PDF 1.5MB)
Targeted Therapies
Frank Douglas, PhD, MD Session Chair
Executive Director, Center for Biomedical
Innovation (CBI), MIT

Economics of Stratified Medicine
Ernst Berndt, PhD - Session Chair
Louis V. Seley Professor of Applied Economics,
Sloan School of Management, MIT

1:20-1:40PM

Perspectives on CNS Drug Discovery and Development
Scott Gottlieb, M.D.
Deputy Commissioner of Medical and Scientific Affairs, FDA

1:40-2:00PM

Perspectives on CNS Drug Discovery and Development (PDF 1MB)
Stephen Furlong, Ph.D
Director, Discovery Medicine, AstraZeneca

2:00-2:20PM

Perspectives on CNS Drug Discovery and Development
Eiry W. Roberts, MB (Hons) BS, BSc MRCP
VP, Research Technology & Exploratory Medicine, Eli Lilly and Company

2:20-2:50PM

Panel Discussion
Frank Douglas, Ph.D., M.D. Moderator
Executive Director, CBI, MIT
Session 3 participants

3:10-3:30PM

Session 4: The Practice of Personalized Neurology and Psychiatry (PDF 2.5MB)
Gualberto Ruano, M.D., Ph.D. Session Chair
President and CEO, Genomas

3:30-3:50PM

The Role of a Standardized Brain Database in Personalized Medicine (PDF 2MB)
Evian Gordon, Ph.D., Chairman and CEO, The Brain Resource Company

3:50-4:10PM

The Clinicians Perspective on Personalized Approaches to Treatment of Mental Illness (PDF 3.5MB)
Scott Rauch, M.D.
Associate Chief of Psychiatry for Neuroscience Research, Massachusetts General Hospital

4:10-4:30PM

4:30-5:00PM

Panel Discussion
Gualberto Ruano, M.D., Ph.D. - Moderator
President and CEO, Genomas Session 4 participants

5:00-5:15PM

Closing Remarks (PDF 1.5MB)
Frank Douglas, PhD, MD
Executive Director, CBI, MIT